{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-123543","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.523361+00:00","generated_at":"2026-05-15T08:57:57.487796+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer","bullets":["Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.","Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).","Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).","Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-123543","json":"https://secwatch.observer/filing/0001193125-26-123543.json","markdown":"https://secwatch.observer/filing/0001193125-26-123543.md","text":"https://secwatch.observer/filing/0001193125-26-123543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/0001193125-26-123543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:57:57.487796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}